CYP17 gene polymorphism and prostate cancer susceptibility in a Tunisian population

Souiden, Yousra; Mahdouani, Manel; Chaieb, Kamel; Elkamel, R.; Mahdouani, Kacem

doi:10.1016/j.canep.2010.11.008

Cited by 13 publications

(8 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study has reported association of the polymorphic enzyme glutathione‐S‐transferase T1 (GSTT1) with PCa risk in Tunisian population. In humans, this enzyme is involved in the detoxification of many toxic and potentially carcinogenic compounds such as those found in tobacco smoking (Souiden et al. , 2011).…”

Section: Introductionmentioning

confidence: 99%

Analysis of KIR gene frequencies and HLA class I genotypes in prostate cancer and control group

Portela

Jobim

Salim

et al. 2012

Int J Immunogenetics

View full text Add to dashboard Cite

Prostate cancer is the second most common cancer in men, with a significant increase in incidence and mortality in men over 50 years of age. Natural killer cells (NK) are part of the innate immune system recognizing class I HLA molecules on target cells through their membrane receptors, called killer cell immunoglobulin-like receptors (KIR). The aim of our study is to evaluate the association between the KIR genes and HLA alleles in patients with prostate cancer and healthy controls. Two hundred patients with prostate cancer and 185 healthy controls were typed for HLA class I and KIR genes by PCR-SSP. When both groups were compared, no significant differences were found for HLA-C group 1 and group 2, HLA-Bw4, HLA-A3 and A11. No difference was seen either in KIR frequency between patients with prostate cancer and controls. In conclusion, our data suggest no potential role for the KIR gene system in prostate cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Analysis of KIR gene frequencies and HLA class I genotypes in prostate cancer and control group

Portela

Jobim

Salim

et al. 2012

Int J Immunogenetics

View full text Add to dashboard Cite

show abstract

“…Figure 1 shows the results of literature search and study. For pooling MAF, a total of 418, 350, and 1,832 studies were identified from PubMed, Embase, and Web of Science, respectively, of which 13 case-control studies (Habuchi et al, 2000; Allen et al, 2001; Haiman et al, 2001; Zmuda et al, 2001; Madigan et al, 2003; Tigli et al, 2003; Gunes et al, 2007; Onen et al, 2007; Sobti et al, 2008; Souiden et al, 2011; Antognelli et al, 2013; El Ezzi et al, 2014; Kumar et al, 2014) reporting the MAF in non-BPH populations in two ethnicities (Caucasian and Oriental) were included for pooling minor allele prevalence. For gene effect, a total of 19, 21, and 33 studies were identified from PubMed, Embase, and Web of Science, respectively, of which eight case-control studies (Habuchi et al, 2000; Madigan et al, 2003; Tigli et al, 2003; Gunes et al, 2007; Sobti et al, 2008; Antognelli et al, 2013; El Ezzi et al, 2014; Kumar et al, 2014) were included in the present meta-analysis for pooling gene effect between CYP17 rs743572 polymorphism and BPH.…”

Section: Resultsmentioning

confidence: 99%

Role of CYP17 rs743572 Polymorphism in Benign Prostatic Hyperplasia: A Multivariate Integrated Analysis

et al. 2019

View full text Add to dashboard Cite

Objective: Many published studies have investigated the association between CYP17 rs743572 polymorphism and benign prostatic hyperplasia (BPH) susceptibility but have yielded inconsistent results. Hence, we performed this meta-analysis using the multivariate statistic method to address a more precise association. Methods: Case-control or cohort studies with adequate genotype distribution or minor allele frequency (MAF) were identified by searching the PubMed, Embase, and Web of Science databases up to December, 2018. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to estimate the association between CYP17 rs743572 polymorphism and BPH susceptibility. Results: Pooled MAFs of 13 studies were 37% in Caucasians and 56% in Orientals, respectively. Pooled results of 8 studies suggested that CYP17 rs743572 was not associated with the BPH susceptibility in the overall population (OR = 0.98, 95% CI: 0.80–1.20 for A2 vs. A1; OR = 0.99, 95% CI: 0.79–1.25 for A1/A2 vs. A1/A1; OR = 0.97, 95% CI: 0.62–1.53 for A2/A2 vs. A1/A1). Sensitivity analysis showed the results were robust. Subgroup analysis based on ethnicity suggested that, in Orientals, A2 allele carriers had a 28% lower risk of developing BPH compared with A1 allele carriers, and the risk of BPH is 47% lower in A2/A2 genotype carriers compared with A1/A1 genotype carriers. No significant association was observed in Caucasians. Conclusion: In conclusion, our study indicates a negative association between CYP17 and BPH in Orientals. However, due to limited sample size, the conclusion should be interpreted with caution.

show abstract

“…Studies that have reported a relationship between CYP17A1 gene polymorphism and the risk of PCa have been contradictory in terms of which allele is associated with the increased risk for PCa. Some case-control studies have reported an elevated risk for PCa being related to the A1/A2 or A2/A2 genotype (Lunn et al 1999;Gsur et al 2000;Haiman et al 2001;Kittles et al 2001;Yamada et al 2001;Sobti et al 2008;Souiden et al 2011), whereas other studies indicate an association between PCa and the A1/A1 genotype (Wadelius et al 1999;Habuchi et al 2000). Further studies have reported no difference in the distribution of the various alleles among healthy controls and PCa patients (Chang et al 2001;Latil et al 2001;Standford et al 2002;dos Santos et al 2002;Madigan et al 2003;Hamada et al 2007;Sivonova et al 2012;Cai et al 2012;KarimpurZahmatkesh et al 2013;Ersekerci et al 2015;Han et al 2015;Henríquez-Hernández et al 2015).…”

Section: Cyp17a1 Rs743572 Gene Polymorphismmentioning

confidence: 97%

“…A few epidemiologic studies have determined a positive association between this polymorphism and the Gleason score/clinical stage and serum PSA levels (Sobti et al 2006(Sobti et al , 2008 but many more conclusions are negative (Haiman et al 2001;Stanford et al 2002;Madigan et al 2003;Mononem et al 2006;Okugi et al 2006;Hamada et al 2007;Wright et al 2010;Risio et al 2011;Souiden et al 2011;Sivonova et al 2012;Yamada et al 2013;Han et al 2015;Henríquez-Hernández et al 2015;Brureau et al 2016;Song et al 2016). Some of the studies suggest that the CYP17A1 gene is a risk factor for PCa in males of advanced age (Souiden et al 2011;Song et al 2016). Hamada et al (2007) have reported that the CYP17A1 polymorphism is a potential prognostic predictor for survival in patients with androgen-independent disease, because patients who carry the CYP17A1 variant A2 allele have a longer survival time than patients who do not carry this variant.…”

Section: Cyp17a1 Rs743572 Gene Polymorphismmentioning

confidence: 99%

The role of CYP17A1 in prostate cancer development: structure, function, mechanism of action, genetic variations and its inhibition

Sivoňová

Jurečeková²,

Tatarková³

et al. 2017

gpb

View full text Add to dashboard Cite

Abstract. Androgens play an important role during the development of both normal prostate epithelium and prostate cancer and variants of genes involved in androgen metabolism may be related to an increased risk of prostate disease. Cytochrome P450 17α-hydroxylase/17,20-lyase (CYP17A1) is a key regulatory enzyme in the steroidogenic pathway; it catalyses both 17α-hydroxylase and 17,20-lyase activities and is essential for the production of both androgens and glucocorticoids. In this review, we focus on the structure and enzymatic activity of CYP17A1 and the mechanism of modulation of CYP17A1 activities. We discuss the relationship between common genetic variations in CYP17A1 gene and prostate cancer risk and the main effects of these variations on the prediction of susceptibility and clinical outcomes of prostate cancer patients. The mechanism of action, the efficacy and the clinical potential of CYP17A1 inhibitors in prostate cancer are also summarized.

show abstract

CYP17 gene polymorphism and prostate cancer susceptibility in a Tunisian population

Cited by 13 publications

References 48 publications

Analysis of KIR gene frequencies and HLA class I genotypes in prostate cancer and control group

Analysis of KIR gene frequencies and HLA class I genotypes in prostate cancer and control group

Role of CYP17 rs743572 Polymorphism in Benign Prostatic Hyperplasia: A Multivariate Integrated Analysis

The role of CYP17A1 in prostate cancer development: structure, function, mechanism of action, genetic variations and its inhibition

Contact Info

Product

Resources

About